Abbott (ABT) Faces 20% Drop Amid Earnings Concerns and Lawsuit
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowAbbott Laboratories (ABT) has seen its stock decline 20% this year, influenced by a recent earnings report and ongoing legal issues concerning its special baby formula. Jim Cramer highlighted that Abbott recently acquired Exact Sciences for approximately $21 billion, a deal representing a 51% premium over its prior trading price, marking the largest healthcare merger in two years. Despite this acquisition, Abbott's stock has fallen more than $6 in two days following the announcement. Investors are cautious and awaiting additional insights during the upcoming earnings call to assess future growth potential.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Abbott Laboratories (ABT)
Abbott Laboratories is a diversified healthcare company spanning diagnostics, medical devices, and nutrition.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ABT news
- Abbott (ABT) Jury Orders $53 Million Payment in Formula Case
- Abbott Laboratories Completes Acquisition of Exact Sciences, Strengthens Market Position
- Abbott Laboratories Q3 Earnings Report Shows $1.15 Earnings Per Share
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
